Berry-Kravis, Elizabeth
Hagerman, Randi
Budimirovic, Dejan
Erickson, Craig
Heussler, Helen
Tartaglia, Nicole
Cohen, Jonathan
Tassone, Flora
Dobbins, Thomas
Merikle, Elizabeth
Sebree, Terri
Tich, Nancy
Palumbo, Joseph M.
O’Quinn, Stephen
Funding for this research was provided by:
Zynerba Pharmaceuticals, Inc.
Article History
Received: 11 March 2022
Accepted: 3 November 2022
First Online: 25 November 2022
Declarations
:
: The protocol for the study was approved by the individual institution Investigational Review Boards (IRB) and Ethic Committees or by the central IRB, WCG IRB.
: Not applicable.
: EB-K, RH, CE, and NTartaglia have received funding from Zynerba Pharmaceuticals for the conduct of the study as investigators and are on scientific advisory board for fragile X syndrome for Zynerba Pharmaceuticals. DB, HH, JC, and FT have received funding from Zynerba Pharmaceuticals for the conduct of the study as investigators. TD and EM are paid consultants for Zynerba Pharmaceuticals. TS, NTich, and SO’Q are employees of Zynerba Pharmaceuticals. JMP was an employee of Zynerba Pharmaceuticals at the time of the study.